Glycaemic benefit of iGlarLixi in insulin‐naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan‐O randomized trial
Pharmacology, Toxicology and Pharmaceutical Science
2
2%
Neuroscience
2
2%
Other
4
5%
Unknown
46
54%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 December 2024.
All research outputs
#12,440,152
of 34,560,275 outputs
Outputs from Diabetes, Obesity & Metabolism
#2,870
of 6,130 outputs
Outputs of similar age
#165,132
of 399,767 outputs
Outputs of similar age from Diabetes, Obesity & Metabolism
#50
of 75 outputs
Altmetric has tracked 34,560,275 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 6,130 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.6. This one is in the 47th percentile – i.e., 47% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 399,767 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 75 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.
